- Home
- SLXN vs KZIA Comparison
SLXN vs KZIA Comparison
Compare SLXN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- KZIA
- Stock Information
- Founded
- SLXN 2008
- KZIA 1994
- Country
- SLXN Israel
- KZIA Australia
- Employees
- SLXN N/A
- KZIA N/A
- Industry
- SLXN
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SLXN
- KZIA Health Care
- Exchange
- SLXN NYSE
- KZIA Nasdaq
- Market Cap
- SLXN 7.3M
- KZIA 5.1M
- IPO Year
- SLXN N/A
- KZIA 1999
- Fundamental
- Price
- SLXN $0.80
- KZIA $6.75
- Analyst Decision
- SLXN Strong Buy
- KZIA Strong Buy
- Analyst Count
- SLXN 1
- KZIA 2
- Target Price
- SLXN $5.00
- KZIA $57.50
- AVG Volume (30 Days)
- SLXN 141.1K
- KZIA 2.6M
- Earning Date
- SLXN 08-21-2025
- KZIA 07-15-2025
- Dividend Yield
- SLXN N/A
- KZIA N/A
- EPS Growth
- SLXN N/A
- KZIA N/A
- EPS
- SLXN N/A
- KZIA N/A
- Revenue
- SLXN N/A
- KZIA $1,549,158.00
- Revenue This Year
- SLXN N/A
- KZIA N/A
- Revenue Next Year
- SLXN N/A
- KZIA N/A
- P/E Ratio
- SLXN N/A
- KZIA N/A
- Revenue Growth
- SLXN N/A
- KZIA 248983.08
- 52 Week Low
- SLXN $0.58
- KZIA $2.86
- 52 Week High
- SLXN $41.85
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- KZIA 53.24
- Support Level
- SLXN N/A
- KZIA $5.98
- Resistance Level
- SLXN N/A
- KZIA $6.65
- Average True Range (ATR)
- SLXN 0.00
- KZIA 0.89
- MACD
- SLXN 0.00
- KZIA -0.27
- Stochastic Oscillator
- SLXN 0.00
- KZIA 21.15
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.